Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ciglenečki I[au]:

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial. Coldiron ME et al. PLoS Med. (2018)

An epidemic of dystonic reactions in central Africa. Peyraud N et al. Lancet Glob Health. (2017)

Hepatitis E: urgent action needed. Ciglenecki I et al. Lancet Gastroenterol Hepatol. (2017)

Search results

Items: 1 to 50 of 63

1.

Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016.

Ferreras E, Matapo B, Chizema-Kawesha E, Chewe O, Mzyece H, Blake A, Moonde L, Zulu G, Poncin M, Sinyange N, Kasese-Chanda N, Phiri C, Malama K, Mukonka V, Cohuet S, Uzzeni F, Ciglenecki I, Danovaro-Holliday MC, Luquero FJ, Pezzoli L.

PLoS One. 2019 Aug 30;14(8):e0219040. doi: 10.1371/journal.pone.0219040. eCollection 2019.

2.

Measles seroprevalence after reactive vaccination campaigns during the 2015 measles outbreak in four health zones of the former Katanga Province, Democratic Republic of Congo.

Keating P, Carrion Martin AI, Blake A, Lechevalier P, Uzzeni F, Gignoux E, Okonta C, Langendorf C, Smit S, Ahuka S, Suchard M, Pukuta E, Degail MA, Hansen L, Kibanza-Kyungu J, Ciglenecki I, Cohuet S.

BMC Public Health. 2019 Aug 22;19(1):1153. doi: 10.1186/s12889-019-7500-z.

3.

Field Suitability and Diagnostic Accuracy of the Biocentric Open Real-Time PCR Platform for Dried Blood Spot-Based HIV Viral Load Quantification in Eswatini.

Kerschberger B, Ntshalintshali N, Mpala Q, Díaz Uribe PA, Maphalala G, Kalombola S, Telila AB, Chawinga T, Maphalala M, Jani A, Phugwayo N, de la Tour R, Nyoni N, Goiri J, Dlamini S, Ciglenecki I, Fajardo E.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):96-104. doi: 10.1097/QAI.0000000000002101.

4.

Successful expansion of community-based drug-resistant TB care in rural Eswatini - a retrospective cohort study.

Kerschberger B, Telnov A, Yano N, Cox H, Zabsonre I, Kabore SM, Vambe D, Ngwenya S, Rusch B, Tombo ML, Ciglenecki I.

Trop Med Int Health. 2019 Oct;24(10):1243-1258. doi: 10.1111/tmi.13299. Epub 2019 Aug 27.

PMID:
31390108
5.

Hepatitis E should be considered a neglected tropical disease.

Azman AS, Ciglenecki I, Wamala JF, Lynch J, Aggarwal R, Rahman M, Wong S, Serafini M, Moussa AM, Dalton HR, Shrestha A, Pant R, Peck R, Gurley ES.

PLoS Negl Trop Dis. 2019 Jul 25;13(7):e0007453. doi: 10.1371/journal.pntd.0007453. eCollection 2019 Jul. No abstract available.

6.

Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis.

Kerschberger B, Schomaker M, Telnov A, Vambe D, Kisyeri N, Sikhondze W, Pasipamire L, Ngwenya SM, Rusch B, Ciglenecki I, Boulle A.

Trop Med Int Health. 2019 Sep;24(9):1114-1127. doi: 10.1111/tmi.13290. Epub 2019 Aug 7.

PMID:
31310029
7.

Reproductive health in humanitarian settings in Lebanon and Iraq: results from four cross-sectional studies, 2014-2015.

Balinska MA, Nesbitt R, Ghantous Z, Ciglenecki I, Staderini N.

Confl Health. 2019 Jun 10;13:24. doi: 10.1186/s13031-019-0210-4. eCollection 2019.

8.

Programmatic outcomes and impact of rapid public sector antiretroviral therapy expansion in adults prior to introduction of the WHO treat-all approach in rural Eswatini.

Kerschberger B, Schomaker M, Ciglenecki I, Pasipamire L, Mabhena E, Telnov A, Rusch B, Lukhele N, Teck R, Boulle A.

Trop Med Int Health. 2019 Jun;24(6):701-714. doi: 10.1111/tmi.13234. Epub 2019 Apr 1.

9.

Increased hepatitis C virus co-infection and injection drug use in HIV-infected fishermen in Myanmar.

Ousley J, Nesbitt R, Kyaw NTT, Bermudez E, Soe KP, Anicete R, Mon PE, Le Shwe Sin Ei W, Christofani S, Fernandez M, Ciglenecki I.

BMC Infect Dis. 2018 Dec 14;18(1):657. doi: 10.1186/s12879-018-3558-y.

10.

Field suitability and diagnostic accuracy of the Biocentric® open real-time PCR platform for plasma-based HIV viral load quantification in Swaziland.

Kerschberger B, Mpala Q, Uribe PAD, Maphalala G, de la Tour R, Kalombola S, Bekele A, Chawinga T, Mliba M, Ntshalintshali N, Phugwayo N, Kabore SM, Goiri J, Dlamini S, Ciglenecki I, Fajardo E.

BMC Infect Dis. 2018 Nov 14;18(1):570. doi: 10.1186/s12879-018-3474-1.

11.

Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland.

Etoori D, Ciglenecki I, Ndlangamandla M, Edwards CG, Jobanputra K, Pasipamire M, Maphalala G, Yang C, Zabsonre I, Kabore SM, Goiri J, Teck R, Kerschberger B.

J Int AIDS Soc. 2018 Oct;21(10):e25194. doi: 10.1002/jia2.25194.

12.

Progress and Challenges in Using Oral Cholera Vaccines to Control Outbreaks: The Médecins Sans Frontières Experience.

Ciglenecki I, Azman AS, Jamet C, Serafini M, Luquero FJ, Cabrol JC.

J Infect Dis. 2018 Oct 15;218(suppl_3):S165-S166. doi: 10.1093/infdis/jiy487.

13.

Retention on ART and predictors of disengagement from care in several alternative community-centred ART refill models in rural Swaziland.

Pasipamire L, Nesbitt RC, Ndlovu S, Sibanda G, Mamba S, Lukhele N, Pasipamire M, Kabore SM, Rusch B, Ciglenecki I, Kerschberger B.

J Int AIDS Soc. 2018 Sep;21(9):e25183. doi: 10.1002/jia2.25183.

14.

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.

Coldiron ME, Assao B, Page AL, Hitchings MDT, Alcoba G, Ciglenecki I, Langendorf C, Mambula C, Adehossi E, Sidikou F, Tassiou EI, De Lastours V, Grais RF.

PLoS Med. 2018 Jun 26;15(6):e1002593. doi: 10.1371/journal.pmed.1002593. eCollection 2018 Jun.

15.

The incubation period of hepatitis E genotype 1: insights from pooled analyses of travellers.

Azman AS, Ciglenecki I, Oeser C, Said B, Tedder RS, Ijaz S.

Epidemiol Infect. 2018 Sep;146(12):1533-1536. doi: 10.1017/S0950268818001097. Epub 2018 May 24.

16.

IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence.

Ousley J, Soe KP, Kyaw NTT, Anicete R, Mon PE, Lwin H, Win T, Cristofani S, Telnov A, Fernandez M, Ciglenecki I.

Public Health Action. 2018 Mar 21;8(1):20-24. doi: 10.5588/pha.17.0087.

17.

Challenges and successes in the implementation of option B+ to prevent mother-to-child transmission of HIV in southern Swaziland.

Etoori D, Kerschberger B, Staderini N, Ndlangamandla M, Nhlabatsi B, Jobanputra K, Mthethwa-Hleza S, Parker LA, Sibanda S, Mabhena E, Pasipamire M, Kabore SM, Rusch B, Jamet C, Ciglenecki I, Teck R.

BMC Public Health. 2018 Mar 20;18(1):374. doi: 10.1186/s12889-018-5258-3.

18.

Risk factors for measles mortality and the importance of decentralized case management during an unusually large measles epidemic in eastern Democratic Republic of Congo in 2013.

Gignoux E, Polonsky J, Ciglenecki I, Bichet M, Coldiron M, Thuambe Lwiyo E, Akonda I, Serafini M, Porten K.

PLoS One. 2018 Mar 14;13(3):e0194276. doi: 10.1371/journal.pone.0194276. eCollection 2018.

19.

Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar.

Bermúdez-Aza EH, Shetty S, Ousley J, Kyaw NTT, Soe TT, Soe K, Mon PE, Tun KT, Ciglenecki I, Cristofani S, Fernandez M.

PLoS One. 2018 Feb 8;13(2):e0191695. doi: 10.1371/journal.pone.0191695. eCollection 2018.

20.

Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia.

Ferreras E, Chizema-Kawesha E, Blake A, Chewe O, Mwaba J, Zulu G, Poncin M, Rakesh A, Page AL, Stoitsova S, Voute C, Uzzeni F, Robert H, Serafini M, Matapo B, Eiros JM, Quilici ML, Pezzoli L, Azman AS, Cohuet S, Ciglenecki I, Malama K, Luquero FJ.

N Engl J Med. 2018 Feb 8;378(6):577-579. doi: 10.1056/NEJMc1711583. No abstract available.

21.

Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia.

Poncin M, Zulu G, Voute C, Ferreras E, Muleya CM, Malama K, Pezzoli L, Mufunda J, Robert H, Uzzeni F, Luquero FJ, Chizema E, Ciglenecki I.

Bull World Health Organ. 2018 Feb 1;96(2):86-93. doi: 10.2471/BLT.16.189241. Epub 2017 Oct 19.

22.

HIV-associated Kaposi's sarcoma in Maputo, Mozambique: outcomes in a specialized treatment center, 2010-2015.

Fardhdiani V, Molfino L, Zamudio AG, Manuel R, Luciano G, Ciglenecki I, Rusch B, Toutous Trellu L, Coldiron ME.

Infect Agent Cancer. 2018 Jan 19;13:5. doi: 10.1186/s13027-018-0177-6. eCollection 2018.

23.

High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan.

Azman AS, Bouhenia M, Iyer AS, Rumunu J, Laku RL, Wamala JF, Rodriguez-Barraquer I, Lessler J, Gignoux E, Luquero FJ, Leung DT, Gurley ES, Ciglenecki I.

Am J Trop Med Hyg. 2017 Jun;96(6):1296-1301. doi: 10.4269/ajtmh.16-0620.

24.

Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.

Coldiron ME, Alcoba G, Ciglenecki I, Hitchings M, Djibo A, Page AL, Langendorf C, Grais RF.

Trials. 2017 Jun 24;18(1):294. doi: 10.1186/s13063-017-2028-y.

25.

Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.

Parker LA, Rumunu J, Jamet C, Kenyi Y, Lino RL, Wamala JF, Mpairwe AM, Muller V, Llosa AE, Uzzeni F, Luquero FJ, Ciglenecki I, Azman AS.

PLoS Negl Trop Dis. 2017 Jun 8;11(6):e0005652. doi: 10.1371/journal.pntd.0005652. eCollection 2017 Jun.

26.

Vaccination against cholera in Juba - Authors' reply.

Ciglenecki I, Azman AS, Rumunu J, Cabrol JC, Luquero FJ.

Lancet Infect Dis. 2017 May;17(5):480-481. doi: 10.1016/S1473-3099(17)30184-6. No abstract available.

PMID:
28447952
27.

Hepatitis E: urgent action needed.

Ciglenecki I.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):154. doi: 10.1016/S2468-1253(17)30007-9. Epub 2017 Feb 9. No abstract available.

PMID:
28404126
28.

The impact of control strategies and behavioural changes on the elimination of Ebola from Lofa County, Liberia.

Funk S, Ciglenecki I, Tiffany A, Gignoux E, Camacho A, Eggo RM, Kucharski AJ, Edmunds WJ, Bolongei J, Azuma P, Clement P, Alpha TS, Sterk E, Telfer B, Engel G, Parker LA, Suzuki M, Heijenberg N, Reeder B.

Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721). pii: 20160302. doi: 10.1098/rstb.2016.0302.

29.

Dissolved organic carbon as potential indicator of global change: A long-term investigation in the northern Adriatic.

Dautović J, Vojvodić V, Tepić N, Ćosović B, Ciglenečki I.

Sci Total Environ. 2017 Jun 1;587-588:185-195. doi: 10.1016/j.scitotenv.2017.02.111. Epub 2017 Feb 24.

PMID:
28242218
30.

Adapting to the global shortage of cholera vaccines: targeted single dose cholera vaccine in response to an outbreak in South Sudan.

Parker LA, Rumunu J, Jamet C, Kenyi Y, Lino RL, Wamala JF, Mpairwe AM, Ciglenecki I, Luquero FJ, Azman AS, Cabrol JC.

Lancet Infect Dis. 2017 Apr;17(4):e123-e127. doi: 10.1016/S1473-3099(16)30472-8. Epub 2017 Jan 19. Review.

PMID:
28109819
31.

An epidemic of dystonic reactions in central Africa.

Peyraud N, Rafael F, Parker LA, Quere M, Alcoba G, Korff C, Deats M, Esteve PB, Cabrol JC, Serafini M, Ciglenecki I, Rull M, Larabi IA, Baud F, Grandesso F, Ilunga BK, Alvarez JC, Newton PN.

Lancet Glob Health. 2017 Feb;5(2):e137-e138. doi: 10.1016/S2214-109X(16)30287-X. No abstract available.

32.

Cholera Rapid Test with Enrichment Step Has Diagnostic Performance Equivalent to Culture.

Ontweka LN, Deng LO, Rauzier J, Debes AK, Tadesse F, Parker LA, Wamala JF, Bior BK, Lasuba M, But AB, Grandesso F, Jamet C, Cohuet S, Ciglenecki I, Serafini M, Sack DA, Quilici ML, Azman AS, Luquero FJ, Page AL.

PLoS One. 2016 Dec 19;11(12):e0168257. doi: 10.1371/journal.pone.0168257. eCollection 2016.

33.

Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study.

Azman AS, Parker LA, Rumunu J, Tadesse F, Grandesso F, Deng LL, Lino RL, Bior BK, Lasuba M, Page AL, Ontweka L, Llosa AE, Cohuet S, Pezzoli L, Sodjinou DV, Abubakar A, Debes AK, Mpairwe AM, Wamala JF, Jamet C, Lessler J, Sack DA, Quilici ML, Ciglenecki I, Luquero FJ.

Lancet Glob Health. 2016 Nov;4(11):e856-e863. doi: 10.1016/S2214-109X(16)30211-X.

34.

Experimental Treatment of Ebola Virus Disease with Brincidofovir.

Dunning J, Kennedy SB, Antierens A, Whitehead J, Ciglenecki I, Carson G, Kanapathipillai R, Castle L, Howell-Jones R, Pardinaz-Solis R, Grove J, Scott J, Lang T, Olliaro P, Horby PW; RAPIDE-BCV trial team.

PLoS One. 2016 Sep 9;11(9):e0162199. doi: 10.1371/journal.pone.0162199. eCollection 2016.

35.

Enhanced viral activity and dark CO2 fixation rates under oxygen depletion: the case study of the marine Lake Rogoznica.

Rastelli E, Corinaldesi C, Petani B, Dell'Anno A, Ciglenečki I, Danovaro R.

Environ Microbiol. 2016 Dec;18(12):4511-4522. doi: 10.1111/1462-2920.13484. Epub 2016 Aug 25.

PMID:
27501196
36.

Bacterial diversity across a highly stratified ecosystem: A salt-wedge Mediterranean estuary.

Korlević M, Šupraha L, Ljubešić Z, Henderiks J, Ciglenečki I, Dautović J, Orlić S.

Syst Appl Microbiol. 2016 Sep;39(6):398-408. doi: 10.1016/j.syapm.2016.06.006. Epub 2016 Jul 21.

PMID:
27475818
37.

Population-Level Effect of Cholera Vaccine on Displaced Populations, South Sudan, 2014.

Azman AS, Rumunu J, Abubakar A, West H, Ciglenecki I, Helderman T, Wamala JF, Vázquez Ode L, Perea W, Sack DA, Legros D, Martin S, Lessler J, Luquero FJ.

Emerg Infect Dis. 2016 Jun;22(6):1067-70. doi: 10.3201/eid2206.151592.

38.

Sequelae of Ebola virus disease: the emergency within the emergency.

Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch DG.

Lancet Infect Dis. 2016 Jun;16(6):e82-e91. doi: 10.1016/S1473-3099(16)00077-3. Epub 2016 Mar 22. Review.

PMID:
27020309
39.

Ebola Virus Disease Complications as Experienced by Survivors in Sierra Leone.

Tiffany A, Vetter P, Mattia J, Dayer JA, Bartsch M, Kasztura M, Sterk E, Tijerino AM, Kaiser L, Ciglenecki I.

Clin Infect Dis. 2016 Jun 1;62(11):1360-1366. doi: 10.1093/cid/ciw158. Epub 2016 Mar 21.

40.

Correction: The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study.

Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J.

PLoS Med. 2016 Mar 11;13(3):e1001989. doi: 10.1371/journal.pmed.1001989. eCollection 2016 Mar. No abstract available.

41.

Mortality Rates during Cholera Epidemic, Haiti, 2010-2011.

Luquero FJ, Rondy M, Boncy J, Munger A, Mekaoui H, Rymshaw E, Page AL, Toure B, Degail MA, Nicolas S, Grandesso F, Ginsbourger M, Polonsky J, Alberti KP, Terzian M, Olson D, Porten K, Ciglenecki I.

Emerg Infect Dis. 2016 Mar;22(3):410-6. doi: 10.3201/eid2203.141970.

42.

Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease.

Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D, Tiffany A, Petrucci R, Sterk E, Potet J, Suzuki M, Kurth A, Cannas A, Bocquin A, Strecker T, Logue C, Pottage T, Yue C, Cabrol JC, Serafini M, Ciglenecki I.

N Engl J Med. 2016 Jan 7;374(1):23-32. doi: 10.1056/NEJMoa1504605.

43.

Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study.

Grout L, Martinez-Pino I, Ciglenecki I, Keita S, Diallo AA, Traore B, Delamou D, Toure O, Nicholas S, Rusch B, Staderini N, Serafini M, Grais RF, Luquero FJ.

PLoS Negl Trop Dis. 2015 Dec 29;9(12):e0004274. doi: 10.1371/journal.pntd.0004274. eCollection 2015 Dec.

44.

The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan.

Abubakar A, Azman AS, Rumunu J, Ciglenecki I, Helderman T, West H, Lessler J, Sack DA, Martin S, Perea W, Legros D, Luquero FJ.

PLoS Med. 2015 Nov 17;12(11):e1001901. doi: 10.1371/journal.pmed.1001901. eCollection 2015 Nov. No abstract available.

45.

The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study.

Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J.

PLoS Med. 2015 Aug 25;12(8):e1001867. doi: 10.1371/journal.pmed.1001867. eCollection 2015 Aug. Erratum in: PLoS Med. 2016 Mar;13(3):e1001989.

46.

Long-term efficacy of a hepatitis E vaccine.

Azman AS, Luquero FJ, Ciglenecki I.

N Engl J Med. 2015 Jun 4;372(23):2265. doi: 10.1056/NEJMc1504302. No abstract available.

PMID:
26039605
47.

Geographic distribution and mortality risk factors during the cholera outbreak in a rural region of Haiti, 2010-2011.

Page AL, Ciglenecki I, Jasmin ER, Desvignes L, Grandesso F, Polonsky J, Nicholas S, Alberti KP, Porten K, Luquero FJ.

PLoS Negl Trop Dis. 2015 Mar 26;9(3):e0003605. doi: 10.1371/journal.pntd.0003605. eCollection 2015 Mar.

48.

Community shift from phototrophic to chemotrophic sulfide oxidation following anoxic holomixis in a stratified seawater lake.

Pjevac P, Korlević M, Berg JS, Bura-Nakić E, Ciglenečki I, Amann R, Orlić S.

Appl Environ Microbiol. 2015 Jan;81(1):298-308. doi: 10.1128/AEM.02435-14. Epub 2014 Oct 24.

49.

Use of Vibrio cholerae vaccine in an outbreak in Guinea.

Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Diallo AA, Itama C, Page AL, Quilici ML, Mengel MA, Eiros JM, Serafini M, Legros D, Grais RF.

N Engl J Med. 2014 May 29;370(22):2111-20. doi: 10.1056/NEJMoa1312680.

50.

First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.

Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, Grais RF.

PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2465. doi: 10.1371/journal.pntd.0002465. eCollection 2013.

Supplemental Content

Loading ...
Support Center